As of Thursday close, Guardant Health Inc.’s (NASDAQ:GH) stock was down -$1.31, moving down -4.78 percent to $26.11. The average number of shares traded per day over the past five days has been 1,935,460 shares. 1 time new highs have been achieved over the past 5 days, with a -$4.65 fall in that time frame. In the last twenty days, the average volume was 1,885,735, while in the previous 50 days, it was 1,536,502.
Since last month, GH stock retreated -28.54%. Shares of the company fell to $26.05 on 09/21/23, the lowest level in the past month. A 52-week high of $62.75 was reached on 08/30/23 after having rallying from a 52-week low of $20.67. Since the beginning of this year, GH’s stock price has dropped by -4.01% or -$1.09, and marked a new high 21 times. However, the stock has declined by -58.39% since its 52-week high.
GH stock investors should be aware that Guardant Health Inc. (GH) stock had its last reported insider trading activity 10 days ago on Sep 12. Kalia Kumud, the Chief Information Officer of the company, disposed of 2,125 shares for $32.59 on Sep 12. It resulted in a $69,254 divestment by the insider. Joyce Meghan V. sold 100 shares at an average price of $35.01 on Sep 05. The insider now owns 4,323 shares following the transaction. On Jun 15, Director Joyce Meghan V. sold 2,766 shares at $37.55 apiece. The transaction was valued at $103,863.
Valuation Metrics
The stock’s beta is 0.92. Besides these, the trailing price-to-sales (P/S) ratio of 6.27, the price-to-book (PB) ratio of 9.71.
Financial Health
In the three months ended June 30, Guardant Health Inc.’s quick ratio stood at 6.70, while its current ratio was 7.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 30 was 3.89, and the total debt-to-equity ratio was 3.89. On the profitability front, the trailing twelve-month gross margin is 61.90% percent. Based on annual data, GH earned $293.21 million in gross profit and brought in $449.54 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -46.00%. Return on equity (ROE) for the past 12 months was -427.90%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. GH’s revenue rose 20.42% to $128.71 million during the quarter, while net income inched up to $137.15 million. While analysts expected Guardant Health Inc. to report -$1.17 quarterly earnings, the actual figure was -$0.67 per share, beating the consensus estimate by 42.70%. During the quarter, the company generated -$110.42 million in EBITDA. The liabilities of Guardant Health Inc. were 1.55 billion at the end of its most recent quarter ended June 30, and its total debt was $1.36 billion. The value of shareholders’ equity is $117.69 million.
Technical Picture
This quick technical analysis looks at Guardant Health Inc.’s (GH) price momentum. With a historical volatility rate of 27.29%, the RSI 9-day stood at 13.59% on 21 September.
With respect to its five-day moving average, the current Guardant Health Inc. price is down by -15.12% percent or -$4.65. At present, GH shares trade -31.74% below its 20-day simple moving average and +15.74% percent above its 100-day simple moving average. However, the stock is currently trading approximately -30.85% below its SMA50 and -51.48% below its SMA200.
Stochastic coefficient K was 0.54% and Stochastic coefficient D was 0.47%, while ATR was 1.61. Given the Stochastic reading of 0.42% for the 14-day period, the RSI (14) reading has been calculated as 21.18%. As of today, the MACD Oscillator reading stands at -2.73, while the 14-day reading stands at -4.51.
Analyst Ratings
Guardant Health Inc. (GH) has been rated Buy by analysts. According to 0 brokerage firms, GH is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Guardant Health Inc. stock as buy, with 16 recommending it as overweight.
With a median target price of $54.00, the current consensus forecast for the stock is $40.00 – $85.00. Based on these forecasts, analysts predict Guardant Health Inc. (GH) will achieve an average price target of $55.56.
